COVINGTON, La.--(BUSINESS WIRE)--TCA Cellular Therapy, LLC has enrolled its first patient to participate in the U.S. Food and Drug Administration (FDA) first adult stem cell clinical trial to treat spinal cord injuries. Enrollee and Marine Veteran, Matt Cole was paralyzed from the chest down in a 2005 insurgent attack in Iraq.

“I’m very encouraged by the results of the pre-clinical trials and anticipate this may become a significant therapy for these patients in the near future.”
According to the National Spinal Cord Injury Statistical Center (February 2010), it is estimated that up to 311,000 people in the U.S. are living...